KR970703784A - Medicinal uses of bromelain - Google Patents

Medicinal uses of bromelain

Info

Publication number
KR970703784A
KR970703784A KR1019960707424A KR19960707424A KR970703784A KR 970703784 A KR970703784 A KR 970703784A KR 1019960707424 A KR1019960707424 A KR 1019960707424A KR 19960707424 A KR19960707424 A KR 19960707424A KR 970703784 A KR970703784 A KR 970703784A
Authority
KR
South Korea
Prior art keywords
bromelain
medicament
preventing
manufacture
administering
Prior art date
Application number
KR1019960707424A
Other languages
Korean (ko)
Inventor
트레시 리헤니 미노트
크리스천 인그워다
Original Assignee
크리스토퍼 로저스
코어텍스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스토퍼 로저스, 코어텍스 리미티드 filed Critical 크리스토퍼 로저스
Publication of KR970703784A publication Critical patent/KR970703784A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

브로멜라인, 파인애플 줄기에서 유도된 효소의 혼합물이 세포내 신호 형질도입의 조절체, 특히 이노시톨 인산염의 역할을 하는 경로의 조절체이므로, 이들 세포내 신호경로에 의하여 매개되는 여러가지 질병과 증상이 치료에 유용함을 알았다.Since mixtures of enzymes derived from bromelain and pineapple stems are regulators of intracellular signal transduction, particularly inositol phosphates, various diseases and symptoms mediated by these intracellular signaling pathways are treated. I found it useful.

Description

브로멜라인의 의약적 용도Medicinal uses of bromelain

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (29)

이노시톨 인산염, 단백질 키나아제와/또는 단백질 포스파타아제에 따르는 세포내 신호경로의 조절제 제조에서의 브로멜라인의 용도.Use of bromelain in the preparation of modulators of intracellular signaling pathways following inositol phosphate, protein kinases and / or protein phosphatase. 제1항에 있어서, 신호경로가 이노시톨 인산염에 따르는 용도.2. Use according to claim 1, wherein the signal pathway is according to inositol phosphate. 제1항 또는 제2항에 있어서, 조절제가 세포 성장과 증식을 억제하는 경로를 조절하는 용도.The use of claim 1 or 2, wherein the modulator modulates a pathway that inhibits cell growth and proliferation. 제3항에 있어서, 세포에 의하여 성장인자의 생성을 감소시키거나 방지하는 약제의 제조에서의 용도.4. Use according to claim 3 in the manufacture of a medicament for reducing or preventing the production of growth factors by cells. 제4항에 있어서, MAP키나아제 형성을 예방하는 약제의 제조에서의 용도.Use according to claim 4 in the manufacture of a medicament for preventing MAP kinase formation. 이노시톨 인산염, 단백질 키나아제와/또는 단백질 포스파타아제-매개 세포내신호 형질도입에 의하여 매개되는 질병의 치료 또는 억제용 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for the treatment or inhibition of diseases mediated by inositol phosphate, protein kinases and / or protein phosphatase-mediated intracellular signal transduction. 시토킨 생성을 조절하는 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for regulating cytokine production. 제7항에 있어서,약제가 시토킨 생성을 자극하는 용도.Use according to claim 7, wherein the medicament stimulates cytokine production. 제8항에 있어서, 약제를 면역강화제와/또는 백신용 보조제로서 사용하는 용도.Use according to claim 8, wherein the medicament is used as an adjuvant and / or adjuvant for the vaccine. 제7항에 있어서, 약제가 시토킨 생성을 억제하는 용도.Use according to claim 7, wherein the medicament inhibits cytokine production. 제10항에 있어서, 약제가 면역억제제인 용도.Use according to claim 10, wherein the medicament is an immunosuppressive agent. 제11항에 있어서, 약제가 조직 거부 예방 또는 치료용, 또는 자가면역 반응예방용역인 용도.Use according to claim 11, wherein the medicament is for preventing or treating tissue rejection or for preventing autoimmune response. 제10항에 있어서, 약제가 독성충격의 예방 또는 치료용인 용도.Use according to claim 10, wherein the medicament is for the prevention or treatment of a toxic shock. 자가면역 질병 또는 숙주에 의한 이식거부의 치료 또는 예방의 제조에서의 브로멜라인 용도.Use of bromelain in the manufacture of the treatment or prophylaxis of transplant rejection by an autoimmune disease or host. 제14항에 있어서, 자가면역 질병이 다중 경화증 또는 류머티스성 관절염인 용도.Use according to claim 14, wherein the autoimmune disease is multiple sclerosis or rheumatoid arthritis. 독성충격의 예방 또는 치료용 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for the prevention or treatment of a toxic shock. 백신의 보조제용 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for adjuvant of a vaccine. 암치료용 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for the treatment of cancer. 알레르기의 예방 또는 치료용 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for the prevention or treatment of allergies. 유효량의 브로멜라인을 환자에게 투여하여서하는, 자가면역 질병의 치료 또는 예방 방법.A method of treating or preventing autoimmune diseases, by administering an effective amount of bromelain to a patient. 유효량의 브로멜라인을 환자에게 투여하여서하는 이식거부의 치료 또는 예방 방법.A method of treating or preventing transplant rejection by administering an effective amount of bromelain to a patient. 유효량의 브로멜라인을 환자에게 투여하여서하는 독성충격의 치료 또는 예방 방법.A method of treating or preventing a toxic shock by administering an effective amount of bromelain to a patient. 유효량의 브로멜라인과 함께 백신을 환자에게 투여하여서하는 면역자극을 유도하는 방법.A method of inducing immunostimulation by administering a vaccine to a patient with an effective amount of bromelain. 아포프토시스를 예방하는 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for preventing apoptosis. 유효량의 브로멜라인을 환자에게 투여하여서하는 아포프토시스의 예방방법.A method for preventing apoptosis by administering an effective amount of bromelain to a patient. 기생균과/또는 병원균 감염의 억제, 예방 또는 치료용 약제의 제조에서의 브로멜라인의 용도.Use of bromelain in the manufacture of a medicament for inhibiting, preventing or treating parasitic and / or pathogenic infections. 유효량의 브로멜라인을 환자에게 투여하여서하는 기생균과/또는 병원균의 억제,예방 또는 치료방법.A method for inhibiting, preventing or treating parasites and / or pathogens by administering an effective amount of bromelain to a patient. 유효량의 브로멜라인을 환자에게 투여하여서하는 암치료 방법.A cancer treatment method by administering an effective amount of bromelain to a patient. 유효량의 브로멜라인을 환자에게 투여하여서하는 알레르기의 예방 또는 치료 방법.A method for preventing or treating allergy by administering an effective amount of bromelain to a patient. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960707424A 1994-06-24 1995-06-26 Medicinal uses of bromelain KR970703784A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9412711A GB9412711D0 (en) 1994-06-24 1994-06-24 Medical use of bromelain
GB9412711.5 1994-06-24
PCT/GB1995/001501 WO1996000082A1 (en) 1994-06-24 1995-06-26 Medical use of bromelain

Publications (1)

Publication Number Publication Date
KR970703784A true KR970703784A (en) 1997-08-09

Family

ID=10757263

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960707424A KR970703784A (en) 1994-06-24 1995-06-26 Medicinal uses of bromelain

Country Status (13)

Country Link
EP (1) EP0766565A1 (en)
JP (1) JPH10502073A (en)
KR (1) KR970703784A (en)
CN (1) CN1151119A (en)
AU (1) AU2749395A (en)
CA (1) CA2193654A1 (en)
FI (1) FI965204A (en)
GB (1) GB9412711D0 (en)
IL (1) IL114331A0 (en)
NO (1) NO965564L (en)
TW (1) TW403654B (en)
WO (1) WO1996000082A1 (en)
ZA (1) ZA955292B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526691D0 (en) * 1995-12-29 1996-02-28 Cortecs Ltd Medical use of proteases
US20020102253A1 (en) 1997-02-25 2002-08-01 Mynott Tracey Lehanne Component of bromelain
JP2001513636A (en) 1997-02-25 2001-09-04 コルテクス（ユーケイ）リミティッド Bromelain ingredients
JP4651756B2 (en) * 1997-02-25 2011-03-16 サランティス プロプライエタリィ リミテッド Isolated protein that is a component of bromelain, therapeutic agent and pharmaceutical composition containing the same
NO304766B1 (en) 1997-06-16 1999-02-08 Sintef fingerprint Sensor
DE19726255C2 (en) * 1997-06-20 2000-03-16 Mucos Pharma Gmbh & Co Influence of cytokines by proteolytic enzymes and rutoside
DE19726244C2 (en) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Use of proteolytic enzymes and rutoside to prevent or treat graft rejection
DE19726254C2 (en) * 1997-06-20 1999-10-21 Mucos Pharma Gmbh & Co Tolerance induction through proteases
GB9713667D0 (en) * 1997-06-27 1997-09-03 Cortecs Ltd Enhancement of intestinal permeability
GB9819137D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Component of bromelain
GB9819138D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Nucleic acids and proteins from pineapple stem
DE19847114A1 (en) * 1998-10-13 2000-04-20 Mucos Pharma Gmbh & Co Use of proteolytic enzymes to modulate hyperactive T cells, especially for symptomatic treatment of immune-mediated inflammatory diseases, e.g. multiple sclerosis, diabetes, arthritis or glomerulonephritis
CA2346448A1 (en) * 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
DE19957318A1 (en) * 1999-11-29 2001-06-21 Mucos Pharma Gmbh & Co Influence of TGF-beta by proteolytic enzymes
DE10018980A1 (en) * 2000-04-17 2001-11-08 Mucos Pharma Gmbh & Co Prophylaxis and therapy of diabetes mellitus I using proteolytic enzymes
EP1208849B1 (en) * 2000-11-28 2015-10-28 URSAPHARM Arzneimittel GmbH Use of bromelain for adjuvant therapy during wound healing process
TW201419131A (en) 2012-11-09 2014-05-16 Health & Life Co Ltd Voice-assisted biomedical sensing apparatus
US9526768B2 (en) * 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225122A (en) * 1983-05-23 1984-12-18 Kaken Pharmaceut Co Ltd Remedy and improver for cancerous cachexia
ES2072280T3 (en) * 1989-10-06 1995-07-16 Mucos Emulsions Gmbh CATABOLIC ENZYMES FOR THE INDUCTION OF THE TUMOR NECROSIS FACTOR (TNF).
DE4302060A1 (en) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Use of bromelain as CD44 surface molecule modifier
GB9313188D0 (en) * 1993-06-25 1993-08-11 Cortecs Ltd Medical use of enzymes

Also Published As

Publication number Publication date
EP0766565A1 (en) 1997-04-09
FI965204A0 (en) 1996-12-23
NO965564D0 (en) 1996-12-23
GB9412711D0 (en) 1994-08-17
JPH10502073A (en) 1998-02-24
TW403654B (en) 2000-09-01
CA2193654A1 (en) 1996-01-04
NO965564L (en) 1997-02-24
CN1151119A (en) 1997-06-04
ZA955292B (en) 1997-07-28
AU2749395A (en) 1996-01-19
FI965204A (en) 1997-02-21
WO1996000082A1 (en) 1996-01-04
IL114331A0 (en) 1995-10-31

Similar Documents

Publication Publication Date Title
KR970703784A (en) Medicinal uses of bromelain
NO307027B1 (en) Use of riluzole in the treatment of neurological lesions related to traumatic injuries
DE60113815D1 (en) TREATMENT OF CYTOKIN-MEDIATED DISEASES WITH TEC FAMILY PROTEIN TYROSINE KINASE INHIBITORS
GEP20032954B (en) Heterocyclic Inhibitors of P38
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
EP0765160A4 (en)
ATE331503T1 (en) TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITING DRUGS
BR0212141A (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammation and other diseases
ATE323482T1 (en) USE OF P38 MAPK INHIBITORS IN THE TREATMENT OF EYE DISEASES
DE69400799D1 (en) USE OF RILUZOL FOR THE TREATMENT OF PARKINSON AND THE PARKINSON SYNDROME
KR900702050A (en) Axon growth regulator
UA35567C2 (en) Pharmaceutical preparation for treating patients with coagulation impairment, method for treatment, method for pharmaceutical manufacturing
DE60233261D1 (en) INHIBITORS OF HUMAN ADAM-10
YU75803A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
DE69820053D1 (en) INTERFERENCE NOTOCORD TO REDUCE SYMPTOMS / TREATMENT OF ARTHRITIS
ATE190839T1 (en) USE OF PRODELPHIDINE TO TREAT ARTHROSIS
ATE223721T1 (en) EDELFOSINE FOR THE TREATMENT OF BRAIN TUMORS
BR0016415A (en) Adenosine kinase inhibitors for the treatment of retinal and optic nerve damage
ES2148268T3 (en) PHARMACEUTICAL COMPOSITION TO PREVENT OR TREAT BONE FRACTURES.
DE69424679D1 (en) COMPOSITION FOR TREATING OR PREVENTING HERPES
MXPA04001255A (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma.
MA27530A1 (en) USE OF LEVOCETIRIZINE FOR THE TREATMENT OF PERSISTENT ALLERGIC RHINITIS.
ATE369143T1 (en) USE OF NGALI NUT OIL TO TREAT/RELIEF ARTHRITIS PAIN AND OTHER SIMILAR DISORDERS
DE69932434D1 (en) Prophylaxis and treatment of autoimmune demyelinating diseases by Fas antagonists
ATE203671T1 (en) IMIDAZOLOQUINOXALINONE FOR THE TREATMENT OF CENTRAL NERVOUS DISEASES

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid